MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New radiation technique tested to prepare patients for Life-Saving stem cell transplants
Disease control TerminatedThis early-phase study is testing the safety and best dose of a targeted radiation treatment, given with two chemotherapy drugs, to prepare patients for a donor stem cell transplant. The goal is to better wipe out cancer cells in the bone marrow before receiving healthy donor cel…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 04, 2026 03:35 UTC
-
Engineered immune cells target Tough-to-Treat leukemia in early trial
Disease control OngoingThis early-stage study is testing a new type of CAR T-cell therapy for adults with acute myeloid leukemia (AML) or a related blood cancer that has come back or not responded to other treatments. Doctors take a patient's or a donor's immune cells, genetically modify them to better…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
New drug combo aims to help CML patients stop treatment
Disease control OngoingThis study is testing if adding an immunotherapy drug called pembrolizumab to standard CML medications can help patients achieve a deeper remission. It is for patients whose cancer is controlled but still detectable at very low levels. The goal is to see if this combination can e…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
New immune therapy trial aims to target tough leukemia
Disease control OngoingThis early-stage study is testing the safety and side effects of a new type of immune cell therapy for adults with B-cell acute lymphoblastic leukemia that has come back or hasn't responded to other treatments. The therapy involves genetically modifying a patient's own immune cel…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Stanford University • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC